Ophthalmology. Retina最新文献

{"title":"The Retrobulbar Spot Sign in Central Retinal Artery Occlusion","authors":"Fernando Pellerano MD, Joseph D. Bogaard MD, PhD","doi":"10.1016/j.oret.2024.12.011","DOIUrl":"10.1016/j.oret.2024.12.011","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Page e79"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to Hydroxychloroquine Dosing Guidelines at the University of California","authors":"Kareem Moussa MD , Jaipreet S. Virk BS , Brian Paciotti PhD, MS , Blythe P. Durbin-Johnson PhD , Jessica G. Shantha MD, Msc , Edmund Tsui MD, MS , Catherine Q. Sun MD , Sally L. Baxter MD, MSc , Charlotte Gore MD , Glenn Yiu MD, PhD","doi":"10.1016/j.oret.2025.03.003","DOIUrl":"10.1016/j.oret.2025.03.003","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Pages 814-817"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143616664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-VEGF Use for Conditions without US Food and Drug Administration Approval","authors":"Ravi Parikh MD, MPH , Elias H. Kahan MD , Casey Zhang MD , Rhiya Mittal MD , Arjun Watane MD , Flora C. Lum MD , Scott M. Friedman MD","doi":"10.1016/j.oret.2025.03.014","DOIUrl":"10.1016/j.oret.2025.03.014","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Pages 817-819"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Dose Bevacizumab 0.03 mg for Treatment of Type 1 Retinopathy of Prematurity","authors":"Thomas W. Hejkal MD, PhD ,&nbsp;Shruti Sinha MBBS, MS ,&nbsp;Pukhraj Rishi MBBS, MS ,&nbsp;Samiksha F. Jain MD ,&nbsp;Paul J. Rychwalski MD","doi":"10.1016/j.oret.2025.02.009","DOIUrl":"10.1016/j.oret.2025.02.009","url":null,"abstract":"<div><h3>Purpose</h3><div>We reviewed outcomes using intravitreal bevacizumab 0.03 mg to treat retinopathy of prematurity (ROP) after switching to this dose in November 2018.</div></div><div><h3>Design</h3><div>Multicenter, retrospective, nonrandomized, nonmasked, consecutive case series.</div></div><div><h3>Subjects and Controls</h3><div>This study included 62 premature infants (123 eyes) diagnosed with type 1 ROP who were treated with low-dose bevacizumab (0.03 mg). A historical control group of infants who had received standard-dose bevacizumab (0.625 mg) was included for comparison.</div></div><div><h3>Methods</h3><div>Results from 62 patients (123 eyes) treated between November 2018 and September 2023 with low-dose intravitreal bevacizumab, 0.03 mg in 0.03 ml, by 4 treating physicians were reviewed.</div></div><div><h3>Main Outcome Measures</h3><div>Primary outcome measures were percentage of eyes having initial regression of ROP and percentage of eyes that received subsequent laser treatment. Secondary outcomes were time between bevacizumab and subsequent laser treatment, number of laser spots, and percentage with recurrence of ROP.</div></div><div><h3>Results</h3><div>All eyes had initial regression of ROP. Of the 123 eyes, 42 (34%) received laser treatment at some point after bevacizumab: 34 (28%) for persistent avascular retina (PAR) and 8 (7%) for reactivation of ROP. The average time between bevacizumab and laser was 16 ± 6 weeks for PAR and 13 ± 5.8 weeks for recurrent ROP. The mean number of laser spots per eye was 496 ± 247 for PAR and 905 ± 915 for recurrent ROP (<em>P</em> = 0.028). No eyes developed stage 4 or stage 5 ROP.</div></div><div><h3>Conclusions</h3><div>Based on historical comparisons, a 0.03-mg dose of intravitreal bevacizumab was as effective as a 0.625-mg dose for treatment of ROP. These data provide additional evidence from clinical practice to support the use of a 0.03-mg dose of bevacizumab for treatment of ROP.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosures may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Pages 807-811"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinal Metastasis Secondary to Lung Cancer Treated with Local Photodynamic Therapy and Systemic Nivolumab","authors":"Mathieu Carriere MD, FRCSC,&nbsp;Kelsey A. Roelofs MD, FRCSC,&nbsp;Parampal S. Grewal MD, FRCSC","doi":"10.1016/j.oret.2024.12.012","DOIUrl":"10.1016/j.oret.2024.12.012","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Page e80"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Risk Retinoblastoma Based on International Classification Systems","authors":"Deepthi E. Kurian MD ,&nbsp;Swathi Kaliki MD ,&nbsp;Carol L. Shields MD","doi":"10.1016/j.oret.2025.01.020","DOIUrl":"10.1016/j.oret.2025.01.020","url":null,"abstract":"<div><h3>Purpose</h3><div>To determine the predictive value of International Intraocular Retinoblastoma Classification schemes and the American Joint Committee on Cancer (AJCC) classification for histopathological high-risk features (HRFs).</div></div><div><h3>Design</h3><div>Multicentric international collaborative retrospective case series.</div></div><div><h3>Subjects</h3><div>One thousand three hundred and sixty-two patients with retinoblastoma from 16 centers and 11 countries.</div></div><div><h3>Intervention</h3><div>Primary enucleation; adjuvant therapy in patients with HRF.</div></div><div><h3>Main Outcome Measures</h3><div>High-risk retinoblastoma defined as 1 or more HRF (anterior segment involvement, massive choroidal invasion, minor choroidal infiltration with prelaminar optic nerve invasion, retrolaminar or resected optic nerve cut end involvement, scleral or microscopic extrascleral infiltration); metastasis-free survival (MFS).</div></div><div><h3>Results</h3><div>Of the 1362 patients, 751 (55.1%) had HRF. According to the International Classification of Retinoblastoma (ICRB) (Philadelphia vs. Los Angeles [LA]) versus Children’s Oncology Group (COG) classification schemes, the positive predictive value (PPV) of group D eyes for HRF was 42.0% versus 35.1% versus 43.2%, respectively, and that for group E eyes was 58.5% versus 59.0% versus 59.5%, respectively. Comparing group D versus group E eyes, there was higher mean number of HRF (standard deviation, range) among group E eyes using the ICRB Philadelphia (0.7 [0.9, 0.0–6.0] vs. 1.3 [1.7, 0.0–9.0], <em>P</em> &lt; 0.001), ICRB LA (0.6 [0.8, 0.0–6.0] vs. 1.3 [1.7, 0.0–9.0], <em>P</em> &lt; 0.001) and COG (0.8 [1.2, 0.0–7.0] vs. 1.3 [1.6, 0.0–8.0], <em>P</em> &lt; 0.001) classifications. The PPV for HRF was above 55% for AJCC clinical tumor (cT) group cT3a with increments through cT3e to 72.3%. An agreement between ICRB Philadelphia versus ICRB LA, ICRB LA versus COG, and ICRB Philadelphia versus COG was 0.9, 0.8, and 0.8, respectively (<em>P</em> &lt; 0.001). Metastasis-free survival rates and overall survival rates were also comparable between all intraocular retinoblastoma classification schemes but better stratified within the AJCC scheme.</div></div><div><h3>Conclusions</h3><div>All intraocular retinoblastoma classification schemes predict HRF and MFS equally. Group E includes a wide spectrum equivalent to the AJCC group cT3. Uniform grouping with subcategorization of group E might improve risk stratification. We propose that everyone across the retinoblastoma world henceforth adopts the AJCC classification for all reporting and publishing.</div></div><div><h3>Financial Disclosure(s)</h3><div>The authors have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Pages 787-797"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Haller’s and Sattler’s Layer Dysplasia—Possible Subtype of Choroidal Dysplasia?","authors":"Zhenlong Ran MD ,&nbsp;Jiayue Wang MD ,&nbsp;Dongyan Pan MD","doi":"10.1016/j.oret.2024.12.019","DOIUrl":"10.1016/j.oret.2024.12.019","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Page e81"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Progression of Myopic Maculopathy in a Long-Term Follow-Up of a European Cohort","authors":"Matteo Mario Carlà MD ,&nbsp;Francesco Boselli MD ,&nbsp;Federico Giannuzzi MD ,&nbsp;Emanuele Crincoli MD ,&nbsp;Fiammetta Catania MD ,&nbsp;Tomaso Caporossi MD, PhD ,&nbsp;Stanislao Rizzo MD ,&nbsp;Carlos Mateo MD","doi":"10.1016/j.oret.2025.02.015","DOIUrl":"10.1016/j.oret.2025.02.015","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the longitudinal progression of myopic maculopathy in a European cohort of highly myopic patients, analyzing the disease natural history and its impact on visual function.</div></div><div><h3>Design</h3><div>Retrospective, observational monocentric cohort study.</div></div><div><h3>Participants</h3><div>The study included 1228 eyes from 781 highly myopic patients with a minimum follow-up time of 5 years. We collected best-corrected visual acuity (BCVA) measurement, axial length (AXL), fundus photography, and spectral-domain OCT, along with data regarding intraocular pressure-lowering drugs and glaucoma surgery.</div></div><div><h3>Methods</h3><div>Myopic atrophic maculopathy (MAM) was graded according to the ATN classification system. The presence of myopic staphyloma followed Curtin’s classification. The development of myopic neovascular maculopathy (MNM) and myopic tractional maculopathy (MTM) was also assessed, along with the presence of dome-shaped macula (DSM) and lacquer cracks (LCs) at baseline.</div></div><div><h3>Main Outcome Measures</h3><div>The rate of MAM progression and visual outcomes. The secondary outcome included the correlation with the presence of staphyloma subtypes and the development of MNM and MTM.</div></div><div><h3>Results</h3><div>The mean AXL was 31.6 ± 2.8 mm. Myopic atrophic maculopathy progressed in 57% of eyes over a mean follow-up of 11.4 years. Eyes with patchy atrophy progressed in 81% of cases, and 47% of them developed macular atrophy, whereas eyes with tessellated fundus progressed in only 19% of cases. The presence of a macular-involving staphyloma was associated with progression, particularly for type IX (86% rate of progression). A significant decline in BCVA (≥2 lines) was observed in 35.8% of eyes and correlated with AXL, glaucoma surgery, patchy atrophy, MNM, and MTM development (all <em>P</em> &lt; 0.05). Active MNM developed in 190 eyes (15%), significantly associated with baseline LCs (odds ratio [OR], 2.56) and DSM (OR, 4.95), determined faster progression toward macular atrophy (OR, 5.91). Myopic tractional maculopathy complications were observed in 314 eyes (26%) and significantly correlated with the presence of a type I and II staphyloma.</div></div><div><h3>Conclusions</h3><div>More than half of eyes with myopic maculopathy tended to progress, in particular in cases with patchy atrophy at baseline and in eyes developing MNM or MTM, which caused worse vision loss during the study period. Although DSM and LCs correlated with neovascular complications, the shape of the posterior staphyloma correlated with tractional complications.</div></div><div><h3>Financial Disclosure(s)</h3><div>The authors have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Pages 774-786"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial Functional and Anatomical Outcomes of High-dose Aflibercept 8 mg in Exudative Neovascular Age-related Macular Degeneration","authors":"Suraj Bala BS ,&nbsp;Gabriel C.S. Barbosa MD ,&nbsp;Nitesh Mohan BS ,&nbsp;Sunil K. Srivastava MD ,&nbsp;Peter K. Kaiser MD ,&nbsp;Ananth Sastry MD ,&nbsp;Amy S. Babiuch MD ,&nbsp;Jonathan Sears MD ,&nbsp;Katherine E. Talcott MD ,&nbsp;Alex Yuan MD ,&nbsp;Aleksandra Rachitskaya MD ,&nbsp;Justis P. Ehlers MD ,&nbsp;Andrew P. Schachat MD ,&nbsp;Phoebe Lin MD ,&nbsp;Sumit Sharma MD ,&nbsp;Danny A. Mammo MD","doi":"10.1016/j.oret.2025.02.002","DOIUrl":"10.1016/j.oret.2025.02.002","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the short-term outcomes of patients with exudative neovascular age-related macular degeneration (nAMD) treated with high-dose aflibercept (HDA) 8.0 mg, focusing on anatomical and functional changes, as well as the feasibility of extending treatment intervals in a clinical practice setting.</div></div><div><h3>Design</h3><div>Retrospective, noncomparative cohort study.</div></div><div><h3>Subjects</h3><div>Two hundred nineteen eyes from 184 patients with nAMD who received ≥3 HDAs between August 2023 and October 2024.</div></div><div><h3>Methods</h3><div>Patients included in this study were either treatment-naïve or had been previously treated with other anti-VEGF agents. Clinical outcomes, including best-corrected visual acuity (BCVA) and macular OCT parameters, were evaluated at baseline and after each HDA.</div></div><div><h3>Main Outcome Measures</h3><div>The primary outcome was the proportion of eyes able to sustain an 8 ± 1-week or longer treatment interval without anatomical deterioration. The secondary outcomes included anatomical and functional changes.</div></div><div><h3>Results</h3><div>The average follow-up time was 22.9 ± 4.9 weeks; 209 eyes (95.4%) were previously treated, and 10 eyes (4.6%) were treatment-naïve. After the first 3 injections, 206 eyes (94.1%) received a fourth HDA, and 70 eyes (31.9%) received a fifth HDA. One hundred two eyes (46.6%) of the total cohort with an interval shorter than 8 weeks after 3 initial injections had persistent macular fluid; 24 eyes (11.0%) were switched to another anti-VEGF agent. Overall, the mean BCVA was 61.9 ± 21.7 ETDRS letters at baseline and 61.7 ± 22.6 at the final visit, with no statistically significant difference observed (<em>P</em> = 0.934). Central subfield thickness and pigment epithelial detachment height remained stable. Significant reductions were observed in subretinal (54.3%–41.1%, <em>P</em> = 0.006) and intraretinal fluid (53.9%–39.3%, <em>P</em> = 0.002). Among previously treated eyes, the mean preswitch treatment interval was 5.8 ± 2.5 weeks and increased to 7.4 ± 2.2 weeks after the 3 initial injections (<em>P</em> &lt; 0.0001).</div></div><div><h3>Conclusions</h3><div>High-dose aflibercept demonstrated stable BCVA and significant reductions in macular fluid during the follow-up period. A considerable proportion of patients were unable to extend treatment intervals to ≥8 weeks due to persistent macular fluid. These findings suggest that HDA maintains functional stability while improving anatomic outcomes, though challenges in managing chronic nAMD in a clinical-practice setting may limit the ability to extend treatment intervals.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Pages 756-766"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular Type 1 Sialidosis","authors":"Prashant D. Tailor MD,&nbsp;Adrian C. Au MD, PhD,&nbsp;Stacy Pineles MD","doi":"10.1016/j.oret.2024.12.009","DOIUrl":"10.1016/j.oret.2024.12.009","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Page e78"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}